臨床泌尿器科67巻9号

2013年08月発行

綜説

筋層非浸潤性膀胱癌治療の問題点と展望

著者： 藤本清秀¹ 穴井智¹ 千原良友¹

所属機関： ¹奈良県立医科大学泌尿器科学教室

ページ範囲：P.651 - P.661

要旨　膀胱癌の初期診断と治療は経尿道的膀胱腫瘍切除術（TURBT）で行われるが，TURBTによる切除と病理診断が確実でなければ，その後不適切な治療が選択され，患者の予後やQOLを悪化させることになる。また，筋層非浸潤性膀胱癌では再発・進展を予防するために，second TURや術後膀注療法を追加することは有用な選択肢であり，また最近普及を見せている蛍光膀胱鏡も有用であるが，研究施設やグループによってTURBT単独治療を含め治療成績は大きく異なっている。本稿では，筋層非浸潤性膀胱癌に対するTURBTと術後補助療法の問題点や今後の課題についての考察を試みた。

参考文献

1）Herr HW：Surgical factors in the treatment of superficial and invasive bladder cancer. Urol Clin North Am 32：157-164, 2005

2）Nieder AN, Brausi M, Lamm D, et al：Management of stage T1 tumors of the bladder：international consensus panel：Urology 66（suppl 6A）：108-125, 2005

3）Turner W：T1G3 bladder tumours：the case for conservative treatment. Eur Urol 45：401-405, 2004

4）Soloway MS and Masters S：Urothelial susceptibility to tumor cell implantation-influence of cauterization. Cancer 46：1158-1163, 1980

5）Flamm J and Dosa S：The significance of bladder quadrant biopsies in patients with primary superficial bladder carcinoma. Eur Urol 16：81-85, 1989

6）Kiemeney LA, Witjes JA, Heijbroek RP, et al：Dysplasia in normal-looking urothelium increases the risk of tumor progression in primary superficial bladder cancer. Eur J Cancer 30A：1621-1625, 1994

7）山田泰之，林祐太郎，郡健二郎，他：表在性膀胱腫瘍の再発危険因子―特にTUR時の非腫瘍部粘膜生検による再発危険度．日泌尿会誌87：61-66，1996

8）Smith G, Elton RA, Beyon LL, et al：Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 55：665-669, 1983

9）Kiemeney LA, Witjes JA, Heijbroek RP, et al：Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? Br J Urol 73：164-171, 1994

10）Herr HW：The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162：74-76, 1999

11）Schips L, Augustin H, Zigeuner RE, et al：Is repeatedtransurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59：220-223, 2002

12）Divrik T, Yildirim U, Eroğlu AS, et al：Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 175：1258-1261, 2006

13）Divrik T, Yildirim U, Zorlu F, et al：The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin：a prospective, randomized clinical trial. J Urol 175：1641-1644, 2006

14）Jakse G, Algaba F, Malmström PU, et al：A second-look TUR in T1 transitional cell carcinoma：why? Eur Urol 45：539-546, 2004

15）Zurkirchen MA, Sulser T, Gaspert A, et al：Second transurethral resection of superficial transitional cell carcinoma of the bladder：a must even for experienced urologists. Urol Int 72：99-102, 2004

of the bladder：Urology 66（Suppl 6A）：90-107, 2005

17）Kriegmair M, Baumgartner R, Knüchel R, et al：Detection of early bladder carcinoma with 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 155：105-110, 1996

18）Zaak D, Hungerhuber E, Schneede P, et al：Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 95：1234-1238, 2002

19）Hungerhuber E, Stepp H, Kriegmair M, et al：Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69：260-264, 2007

20）Jocham D, Witjes F, Wagner S, et al：Improved detection and treatment of bladder cancer using hexaminolevulinate imaging：a prospective, phase Ⅲ multicenter study. J Urol 174：862-866, 2005

21）藤本清秀，松村善昭，三宅牧人，他：膀胱癌における5-aminolevulinic acidを用いた蛍光膀胱鏡下経尿道的腫瘍切除術および尿中剝離細胞に対する光力学的診断．日本レーザー医学会誌30：399-404，2010

22）Inoue K, Fukuhara H, Shimamoto T, et al：Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for non-muscle invasive bladder cancer. Cancer 118：1062-1074, 2012

23）Riedl CR, Daniltchenko D, Koenig F, et al：Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165：1121-1123, 2001

24）Kriegmair M, Zaak D, Rothenberger KH, et al：Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168：475-478, 2002

25）Filbeck T, Pichlmeier U, Knuechel R, et al：Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis：results of a 5-year study. Urologe A 42：1366-1373, 2003

26）Denzinger S, Burger M, Walter B, et al：Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis：8-year results of prospective randomized study. Urology 69：675-679, 2007

27）Daniltchenko D, Riedl CR, Sachs MD, et al：Long-term benefit of 5-aminolevulinic acid fluorescence-assisted transurethral resection of superficial bladder cancer：5-year results of a prospective randomized study. J Urol 174：2129-2133, 2005

28）Kaasinen E, Rintala E, Hellstrom P, et al：Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42：67-174, 2002

29）Sylvester RJ, Oosterlinck W and van der Meijden AP：A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer：a meta-analysis of published results of randomized clinical trials. J Urol 171：2186-2190, 2004

30）Berrum-Svennung I, Granfors T, Jahnson S, et al：A single instillation of epirubicin after TUR of bladder tumors prevents only small recurrences. J Urol 179：101-106, 2008

. Eur Urol 45：600-605, 2004

32）Babjuk M, Oosterlinck W, Sylvester R, et al：EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder：the 2011 update. Eur Urol 59：997-1008, 2011

33）Ozono S, Hinotsu S, Tabata S, et al：Treated natural history of superficial bladder cancer. Jpn J Clin Oncol 31：536-540, 2001

34）Di Lorenzo G, Perdonà S, Damiano R, et al：Gemicitabine versus bacille Calmette-Guerin after initial bacilli Calmette-Guerin failure in non-muscle invasive bladder cancer. Cancer 116：1896-1900, 2010

35）Hendricksen K, van der Heijden A, Cornel E, et al：Two-year follow-up of the phase Ⅱ marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 27：337-342, 2009

transitional cell carcinoma of the bladder：a randomized Southwest Oncology Group Study. J Urol 163：1124-1129, 2000

37）Han RF and Pan JG：Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer?：a meta-analysis of randomized trials. Urology 67：1216-1223, 2006

38）Malmstrom PU, Sylvester RJ, Crawford D, et al：An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle invasive bladder cancer. Eur Urol 56：247-256, 2009

of the bladder：a meta-analysis of the published results of randomized clinical trials. J Urol 174：86-92, 2005

40）Sylvester RJ, Brausi MA, Kirkels WJ, et al：Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57：766-773, 2010

41）Sylvester RJ, van der Meijden A and Lamm DL：Intravesical bacillus Calmette Guerin reduces the risk of progression in patients with superficial bladder cancer：a meta-analysis of the published results of randomized clinical trials. J Urol 168：1964-1970, 2002

42）Lamm D, Colombel M, Persad R, et al：Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol（suppl 7）：651-666, 2008

43）Hinotsu S, Akaza H, Naito S, et al：Maintenance therapy with bacillus Calmette-Guèrin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor for non-muscle invasive bladder cancer. BJU Int 108：187-195, 2011

of the bladder：randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol 17：759-766, 2010

45）中井　靖，桑田真臣，穴井　智，他：筋層非浸潤性膀胱癌に対するBCG維持療法の検討．泌尿器外科24：783-785，2012

46）Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, et al：Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?：results of a prospective randomized trial. J Urol 174：1242-1247, 2005

47）Ojea A, Nogueira JL, Solsona E, et al：A multicentre randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer：low-dose bacillus Calmette-Guerin（27mg）versus very low-dose bacillus Calmette-Guerin（13.5mg）versus mitomycin C. Eur Urol 52：1398-406, 2007

48）Yoneyama T, Ohyama C, Imai A, et al：Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection：historical cohort study. Urology 71：1161-1165, 2008